UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Usefulness of monitoring of B cell depletion in rituximab‐treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study

Clinical and experimental immunology, 2015-04, Vol.180 (1), p.11-18

2015

Volltextzugriff (PDF)

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Annals of the rheumatic diseases, 2008-03, Vol.67 (3), p.302-308

2008

Volltextzugriff (PDF)

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

Annals of the rheumatic diseases, 2012-11, Vol.71 (11), p.1815-1819

2012

Volltextzugriff (PDF)

Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry

Annals of the rheumatic diseases, 2016-06, Vol.75 (6), p.1108-1113

2016

Volltextzugriff (PDF)

Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome

Clinical and experimental immunology, 2007-05, Vol.148 (2), p.281-287

2007

Volltextzugriff (PDF)

Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis

Rheumatology, 2008-08, Vol.47 (8), p.1208-1212

2008

Volltextzugriff (PDF)

Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three‐year prospective study in community‐recruited patients

British journal of rheumatology, 2003-08, Vol.42 (8), p.939-946

2003

Volltextzugriff (PDF)

A cryopyrin-associated periodic syndrome with joint destruction

Rheumatology (Oxford, England), 2007-04, Vol.46 (4), p.709-714

2007

Volltextzugriff (PDF)

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Annals of the rheumatic diseases, 2012-06, Vol.71 (6), p.875-877

2012

Volltextzugriff (PDF)

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab

Rheumatology, 2007-03, Vol.46 (3), p.446-453

2007

Volltextzugriff (PDF)

Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology

Annals of the rheumatic diseases, 2006-01, Vol.65 (1), p.45-50

2006

Volltextzugriff (PDF)

Leflunomide-induced subacute cutaneous lupus erythematosus

Rheumatology (Oxford, England), 2005-06, Vol.44 (6), p.823-824

2005

Volltextzugriff (PDF)

OP0237 Polymorphisms of Gene Implicated in Type 1 Interferon Pathway Are Associated with The Clinical Response of Rituximab at 24 Weeks in Rheumatoid Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.147-148

2016

Volltextzugriff (PDF)

Anti-TNF-alpha-induced systemic lupus syndrome

Clinical rheumatology, 2003-02, Vol.22 (1), p.56

2003

Volltextzugriff (PDF)

Autoantibodies to the 27 C‐terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis

Rheumatology (Oxford, England), 2001-10, Vol.40 (10), p.1126-1134

2001

Volltextzugriff (PDF)

THU0087 One single infusion of rituximab 1g might be sufficient in the long-term management of rheumatoid arthritis patients responding to a first cycle of rituximab (2 × 1g): Results of a 2-year multi-center randomized controlled trial

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.182-182

2013

Volltextzugriff (PDF)

FRI0165 A prediction tool for drug monitoring of adalimumab in rheumatoid arthritis

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A427-A427

2013

Volltextzugriff (PDF)

THU0193 Body Weight and Sex Influence the Pharmacokinetics of Adalimumab in Rheumatoid Arthritis

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A229-A229

2013

Volltextzugriff (PDF)

OP0132 Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in the very early arthritis community-based (VERA) cohort: Slight improvement after excluding erosion criterion

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.98-98

2013

Volltextzugriff (PDF)

FRI0502 After how many time does it become useless to try to classify an inflammatory rheumatism?

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A544-A544

2013

Volltextzugriff (PDF)

AB0052 Tnfa influences rasgrp1 and rasgrp3 expression levels in pbmc, b and t cells

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A801-A801

2013

Volltextzugriff (PDF)

THU0068 Prevalence of dyslipidaemia in an early arthritis rheumatoid cohort (ESPOIR cohort). Lack of improvement after 4 years of follow-up

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.175-176

2013

Volltextzugriff (PDF)

FRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A457-A457

2013

Volltextzugriff (PDF)

THU0107 CCL19, a chemokine involved in B-cell trafficking, is related to the decrease of blood memory B-cells and predicts the clinical response to rituximab in rheumatoid arthritis: Results from the smart study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.190-190

2013

Volltextzugriff (PDF)

THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A221-A222

2013

Volltextzugriff (PDF)

1 – 25 von 297

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(179)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(178)
Female
(114)
Male
(106)
Middle Aged
(102)
Life Sciences & Biomedicine
(98)
Science & Technology
(98)
Adult
(80)
Aged
(76)
Rheumatology
(68)
Biological And Medical Sciences
(56)
Medical Sciences
(56)
Rheumatoid Arthritis
(37)
Diseases Of The Osteoarticular System
(31)
Inflammatory Joint Diseases
(27)
Arthritis, Rheumatoid - Drug Therapy
(22)
Prospective Studies
(22)
Treatment Outcome
(21)
Pharmacology. Drug Treatments
(18)
Adolescent
(17)
Aged, 80 And Over
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Usefulness of monitoring of B cell depletion in rituximab‐treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry

Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome

Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis

Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three‐year prospective study in community‐recruited patients

A cryopyrin-associated periodic syndrome with joint destruction

Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab

Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology

Leflunomide-induced subacute cutaneous lupus erythematosus

OP0237 Polymorphisms of Gene Implicated in Type 1 Interferon Pathway Are Associated with The Clinical Response of Rituximab at 24 Weeks in Rheumatoid Arthritis

Anti-TNF-alpha-induced systemic lupus syndrome

Autoantibodies to the 27 C‐terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis

THU0087 One single infusion of rituximab 1g might be sufficient in the long-term management of rheumatoid arthritis patients responding to a first cycle of rituximab (2 × 1g): Results of a 2-year multi-center randomized controlled trial

FRI0165 A prediction tool for drug monitoring of adalimumab in rheumatoid arthritis

THU0193 Body Weight and Sex Influence the Pharmacokinetics of Adalimumab in Rheumatoid Arthritis

OP0132 Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in the very early arthritis community-based (VERA) cohort: Slight improvement after excluding erosion criterion

FRI0502 After how many time does it become useless to try to classify an inflammatory rheumatism?

AB0052 Tnfa influences rasgrp1 and rasgrp3 expression levels in pbmc, b and t cells

THU0068 Prevalence of dyslipidaemia in an early arthritis rheumatoid cohort (ESPOIR cohort). Lack of improvement after 4 years of follow-up

FRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial

THU0107 CCL19, a chemokine involved in B-cell trafficking, is related to the decrease of blood memory B-cells and predicts the clinical response to rituximab in rheumatoid arthritis: Results from the smart study

THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study

Suchergebnisse filtern